Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce Biotech that still has a strategy for developing cell therapies for autoimmune diseases.
Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce Biotech that still has a strategy for developing cell therapies for autoimmune diseases.